EHA 2021 | Dose modification strategies in high-risk MDS treated with venetoclax and azacitidine
Uwe Platzbecker, MD, University of Leipzig, Leipzig, Germany, discusses dose modification strategies for high-risk myelodysplastic syndromes (MDS) patients treated with venetoclax and azacitidine who are at high risk of developing neutropenia, thrombocytopenia, or other infection complications like pneumonia. The study shows that dose modifications did not alter the efficacy of each drug, and there was no significant difference in hematologic toxicity. Prof. Platzbecker reports that results from this study should inform further clinical studies to investigate further alterations in the dosing of these drugs. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Uwe Platzbecker, MD, has received research support and honoraria from Curis, BMS, Amgen, Novartis and Abbvie.
